Morgan Stanley Maintains Overweight on Jazz Pharmaceuticals, Raises Price Target to $283

Benzinga · 2d ago
Morgan Stanley analyst Jeffrey Hung maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Overweight and raises the price target from $280 to $283.